The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book, which it ...
What Happened: The FTC is disputing “junk patent listings” for diabetes, weight loss, asthma and COPD drugs. This initiative represents the latest endeavor against what the agency perceives as ...
The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications ...
The Federal Trade Commission said it is challenging hundreds of alleged "junk" patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk's blockbuster diabetes drugs ...
On April 30, 2024, the Federal Trade Commission (FTC) announced that it sent a new set of warning letters to ten pharmaceutical companies. The letters inform the companies that the FTC has ...
Boehringer Ingelheim, one of 10 companies sent a warning letter by the FTC disputing the accuracy of patent listings in the ...
The Federal Trade Commission is seemingly seeking to clear the path for generic versions of the weight loss drug Ozempic — but there will be a long road ahead before cheaper versions of the ...
The Federal Trade Commission (FTC) has voted to approve a proposed rule that would ban employers from using non-compete agreements with nearly all employees. The FTC estimated that one in five US ...
At the center of the issue is the Orange Book, an FDA publication containing patents relevant to brand-name pharmaceuticals. If a brand-name manufacturer decides to contest a challenge to an ...
The Federal Trade Commission is seemingly seeking to clear the path for generic versions of the weight loss drug Ozempic — but there will be a long road ahead before cheaper versions of the injectable ...